The plate of new hospital was unvailed on the dedication day.
PRLog (Press Release) –
Feb 05, 2008 – Seoul National University's Veterinary Medical Teaching Hospital (VMTH), on January 30, 2008, celebrated the grand opening of a new clinic for cell therapeutics and animal cloning. The clinic, in collaboration with RNL Bio Co LTD (RNL), will become the center for commercialization of stem cell therapeutics and animal cloning. The clinic will take charge in clinical research and development in stem cell therapeutics and animal cloning, while RNL Bio will manufacture stem cell drugs and pioneering animal health care market .
Professor Hwa-Young Yoon, the director of VMTH, said, "The opening of our new clinic is a small step in the movement towards the implementation of stem cell medicine for animals. We are very please that our pets will benefit from our cutting edge stem cell technology."
"We have plans to enters animal health care market in developed countries like the US, Europe and Japan as well as such emerging market as Dubai", added Dr. Jeong Chan Ra, President and CEO of RNL.
About Veterinary Medical Teaching Hospital of Seoul National University
VMTH opened in 1997 and it serves as a referral hospital covering the almost entire Seoul area and vicinity. The modernized and advanced education is provided and advanced clinical services are practiced. The world first cloned dog, Snuppy, was born in 2005 and their cloning technology is yet unchallenged.
About RNL Bio, CO., LTD.
RNL is a premier biotechnology company in Korea focused on stem cell therapeutics and life sciences technologies. Headquartered in Seoul with a recently opened state-of-the-art GMP facility, RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and strives to become a global leader in the development of stem cell therapeutics. In 2006, RNL established wholly owned US subsidiary, RNL Biostar, for clinical development in the US and for licensing its technologies in North and South America.
